부산대학교 도서관

Objective: To evaluate cisplatin, carboplatin induced ototoxicity in children with head and neck cancer. Material and Methods: Charts of 1095 patients with childhood cancer treated between 1988-2017 were retrospectively evaluated. Patients who received platinum-based chemotheraphy for head and neck cancers were determined. Patients were divided into 3 groups. Group 1 was consisted of patients who received only cisplatin therapy, Group 2 patients received cisplatin+carboplatin therapy and group 3 patients was composed of patients who received only carboplatin therapy. Possible risk factors for the occurence of ototoxicity such as age,gender, various dose of platinum- based therapies, concomitant radiotherapy were evaluated.The audiological tests battery consisted of pure tone audiometry, transient oto-acoustic emissions, auditory brainstem response. Ototoxicity was evaluated according to Brock's criteria. Results: There were 47 patients with head/neck cancer who received platinum. The median-age was 8 years (3mos- 16.8 yrs), Male/Female ratio was 1.14. There were 18 patients in group 1 (cisplatin-only), 7 patients in group 2 (cisplatin+carboplatin),22 patients in group3 (carboplatinonly). Ototoxicity was seen in 15 (32%) patients. 5 patients (33%) had grade(1), 4 patients (27%) had grade(2), 4 patients (27%) had grade(3), two patients (13%) had grade(4) ototoxicity. Ototoxicity incidence was 44% (n:8) in group 1, 71% (n:5) in group 2, and %9 (n:2) in group 3. Ototoxicity incidence was significantly higher in patients who received higher cumulative dose of cisplatin ( ≥400mg/m2) (p:0.040) and in patients who were co-treated with head/ neck radiotherapy (p:0.041). Other evaluated risk factors were not associated with the occurence of ototoxicity. Conclusion: Higher cumulative doses of cisplatin and concomittant head/neck radiotherapy increase the risk of ototoxicity. Audiologic follow-up is necessary for early detection of ototoxicity. [ABSTRACT FROM AUTHOR]